カテゴリ： GlobalData, ドイツ, 企業調査

MorphoSys AG (MOR)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014378
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of cancer, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers Human Combinatorial Antibody Library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It conducts research and development activities with pharmaceutical and biotechnology companies. Morphosys is headquartered in Munich, Germany.

MorphoSys AG (MOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 21
Licensing Agreements 22
MorphoSys Enters Into Licensing Agreement With GSK For MOR103 22
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
MorphoSys Enters into Licensing Agreement with Merck Serono 25
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 26
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 27
MorphoSys Enters Into Licensing Agreement With Novozymes 28
MorphoSys Expands Licensing Agreement With Shionogi 29
Genedata Expands Licensing Agreement with MorphoSys 30
Equity Offering 31
MorphoSys Raises USD124.3 Million in Private Placement of Shares 31
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 33
Acquisition 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 35
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 36
MorphoSys AG – Key Competitors 38
MorphoSys AG – Key Employees 39
MorphoSys AG – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 41
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 43
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 45
Nov 07, 2016: MorphoSys Reports Results for the First Nine Months of 2016 47
Aug 01, 2016: MorphoSys Reports Results for the First Six Months of 2016 49
May 03, 2016: MorphoSys Reports Results for the First Three Months of 2016 51
Mar 02, 2016: MorphoSys Reports Results for Fiscal Year 2015 53
Mar 02, 2016: MorphoSys is in a strong financial position and focuses on own pipeline 56
Corporate Communications 57
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSys’s Chief Scientific Officer 57
Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSyss Dutch Lanthipeptide Subsidiary 58
Product News 59
12/06/2016: MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016 59
11/03/2016: MorphoSys announces data on MOR202 at Upcoming American Society of Hematology Annual Meeting 2016 60
10/17/2016: MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference 61
09/19/2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary 62
09/06/2016: MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL 63
06/06/2016: MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma at ASCO 2016 65
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 66
Clinical Trials 67
Feb 21, 2017: MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 67
Aug 03, 2016: MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL 68
Jun 17, 2016: MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment 69
Jun 06, 2016: MorphoSys Presents Updated Clinical Data for MOR208 in Non-Hodgkins Lymphoma at ASCO 2016 71
Apr 06, 2016: MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma 72
Other Significant Developments 73
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 73
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
MorphoSys AG, Deals By Therapy Area, 2011 to YTD 2017 9
MorphoSys AG, Medical Devices Deals, 2011 to YTD 2017 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 21
MorphoSys Enters Into Licensing Agreement With GSK For MOR103 22
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
MorphoSys Enters into Licensing Agreement with Merck Serono 25
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 26
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 27
MorphoSys Enters Into Licensing Agreement With Novozymes 28
MorphoSys Expands Licensing Agreement With Shionogi 29
Genedata Expands Licensing Agreement with MorphoSys 30
MorphoSys Raises USD124.3 Million in Private Placement of Shares 31
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 33
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 35
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 36
MorphoSys AG, Key Competitors 38
MorphoSys AG, Key Employees 39
MorphoSys AG, Subsidiaries 40

★海外企業調査レポート[MorphoSys AG (MOR)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Integrated BioTherapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Integrated BioTherapeutics Inc (IBT) is a biotechnology company that discovers novel vaccines and therapeutics for infectious diseases. The company's products include polyclonal and monoclonal antibodies raised against emerging pathogens, pan-filovirus antibody candidates, vaccines and thera …
  • Companhia Energetica de Sao Paulo (CESP6)：企業の財務・戦略的SWOT分析
    Companhia Energetica de Sao Paulo (CESP6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Biocept Inc (BIOC)-医療機器分野：企業M&A・提携分析
    Summary Biocept Inc (Biocept) is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers related instrumentation, OncoCEE technology, and analytica …
  • Lego AS：企業の戦略的SWOT分析
    Lego AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • AEON Credit Service (Asia) Co., Ltd.：企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Uelzena eG：企業の戦略・SWOT・財務情報
    Uelzena eG - Strategy, SWOT and Corporate Finance Report Summary Uelzena eG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Tikcro Technologies Ltd (TIKRF)：企業の財務・戦略的SWOT分析
    Summary Tikcro Technologies Ltd (Tikcro) is a biotechnology company that discovers, develops, manufactures and markets antibodies. The company undertakes clinical trials for its pipeline products PD1, PDL1, PDL2, TIGIT and CTLA-4 products, among others. Its products are based on 3D antigens designed …
  • Global Partners LP (GLP)-石油・ガス分野：企業M&A・提携分析
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing company. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the US and Canada to t …
  • The Scripps Research Institute-製薬・医療分野：企業M&A・提携分析
    Summary The Scripps Research Institute (TSRI) is a research and educational organization that conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The institut …
  • Arthur J. Gallagher & Co：企業のM&A・事業提携・投資動向
    Arthur J. Gallagher & Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arthur J. Gallagher & Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Wilbur-Ellis Holdings Inc：企業の戦略的SWOT分析
    Wilbur-Ellis Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Collegium Pharmaceutical Inc (COLL)：企業の財務・戦略的SWOT分析
    Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Arthrex Inc-医療機器分野：企業M&A・提携分析
    Summary Arthrex Inc (Arthrex), formerly, Arthroscopy Excision Instruments Inc., is a medical device company which designs, and manufactures surgical products and solutions used for arthroscopic and minimally invasive orthopedic surgical procedures. The company offers shoulder, knee, elbow, hand and …
  • University of Illinois-製薬・医療分野：企業M&A・提携分析
    Summary University of Illinois (UOL) is a university that offers undergraduate, graduate, and professional programs. The university offers online and continuing education programs such as undergraduate and graduate online degrees. It provides research activities in the areas of alternative, compleme …
  • Pinsent Masons LLP：企業の戦略的SWOT分析
    Pinsent Masons LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • The Medicines Company (MDCO)：製薬・医療：M&Aディール及び事業提携情報
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle …
  • Farmer Bros. Co. (FARM)：企業の財務・戦略的SWOT分析
    Farmer Bros. Co. (FARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Matador Resources Co (MTDR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Matador Resources Co (Matador Resources) is an energy company that explores, develops, and produces crude oil and natural gas resources. The company offers new oil and natural gas prospects for exploring and developing hydrocarbons in the US basins. It carries out exploration, production and …
  • Trillion Energy International Inc (PKPL)：企業の財務・戦略的SWOT分析
    Summary Trillion Energy International Inc (Trillion Energy) formerly Park Place Energy Inc, is an oil and gas company that offers exploration and development of oil and natural gas. The company offers various oil and gas services such as drilling, exploration, development, production, distribution a …
  • Z-Medica LLC：医療機器：M&Aディール及び事業提携情報
    Summary Z-Medica LLC (Z- Medica) is a medical device company that develops and manufactures hemostatic medical devices. The company’s products include sterile nonwoven gauzes, haemostatic sponges impregnated with kaolin, haemostatic bandages and hydrophilic roll dressings. Its QuikClot hemostatic de …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆